Acrux Limited · ASX:ACR
Acrux — Shareholder Meeting (November 2020)
29 slides from Acrux's shareholder meeting presentation, Nov 12, 2020
Slide 1: Acrux Limited Annual General Meeting
For personal use only ACRUX LIMITED (ASX: ACR) ANNUAL GENERAL MEETING 12 November 2020
Slide 2: Chairman – Ross Dobinson
For personal use only Chairman – Ross Dobinson
Slide 3: CEO – Michael Kotsanis
For personal use only CEO – Michael Kotsanis
Slide 4: Important notice and disclaimers
Important notice and disclaimers This presentation contains forward-looking statements which are identified by words such as ‘may’, ‘could’, For personal use only ‘believes’, ‘estimates’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based
Slide 5: Business overview
Business overview 1. Acrux is a specialty topical and transdermal drug development and commercialisation company For personal use only 2. Acrux is a revenue generating pharmaceutical company with an extensive product pipeline of topical generic pharmaceuticals creating additional regulatory and comm
Slide 6: Topical Generics – an attractive $18 billion market segment
Topical Generics – an attractive $18 billion market segment Acrux focus: For personal use only Total market Oral drugs Prescription topical drugs Definition of market Drugs that are Drugs that are applied topically to the Total US prescription (all drugs including NCEs ingested orally skin, eyes, ea
Slide 7: Acrux history
Acrux history • Acrux has over 20 years of experience in the development and commercialisation of topical For personal use only and transdermal pharmaceuticals • Acrux products are currently sold in 38 countries European Union launch for estradiol spray First US FDA Four commercial US FDA Approval A
Slide 8: Revenue generating business model supporting long-term growth
Revenue generating business model supporting long-term growth For personal use only ▪ On market products are generating 1 2 growing royalty revenues for Acrux Product development Generic drug ▪ Through the Acrux GMP* facility with 25 identification and technology specialised scientists, Acrux posses
Slide 9: Acrux product portfolio
Acrux product portfolio The Acrux pipeline will add to the commercialised portfolio of products For personal use only sold through the Acrux network of licensees ▪ Evamist® sold by Perrigo in the United States and Lenzetto® sold by Gedeon Richter in the European Union and a number of other countries
Slide 10: Strong and Consistent returns
Strong and Consistent returns Acrux’s diversified drug development strategy provides more certainty than novel drug development For personal use only Acrux’s generic portfolio strategy Novel drug development Portfolio Strategy Novel drug development will remain Commercial Detailed screening of gener
Slide 11: Acrux partnered pipeline addressable market
Acrux partnered pipeline addressable market Over US$890 million of addressable market value licensed to TruPharma, Amring Pharmaceuticals, Harris Pharmaceutical and Dash Pharmaceuticals in 2020. Profit share payable to Acrux following For personal use only product launches with milestones on selecte
Slide 12: Overview of current licensees
Overview of current licensees For personal use only • Licensed 6 products to sell • Co-development for 1 • Licensed 1 product to sell in the US when approved product to sell in the US in the US when approved by the FDA when approved by the FDA by the FDA • Sells Lenzetto® in 37 • Sells Evamist® in t
Slide 13: Key Investment highlights
Key Investment highlights For personal use only Acrux is a revenue generating pharmaceutical company with an extensive product pipeline of topical generic pharmaceuticals nearing additional regulatory and commercialisation milestones ▪ 2 products on market in 38 countries Focus on ▪ The topical gene
Slide 14: Platform for growth established
Platform for growth established Through investment in the platform over the past 5 years Acrux has a competitive advantage in the identification, development, registration and launch of generic topical drugs For personal use only Acrux Product Status Description Acrux receives royalties on a quarter
Slide 15: Experienced management team with a proven history of commercialising generic drugs
Experienced management team with a proven history of commercialising generic drugs For personal use only CEO & MD Michael Kotsanis leads a team of highly credentialed experts in generic drugs Michael Kotsanis BSc, MBus Felicia Colagrande, BSc(Hons), MBA Product Development and Technical Affairs Dire
Slide 16: CFO – Deborah Ambrosini
For personal use only CFO – Deborah Ambrosini
Slide 17: Full Year Profit and Loss
Full Year Profit and Loss 30 June 30 June 2020 2019 Mvt For personal use only $’000 $’000 Revenue and Other Income Revenue from licensing agreements 1,253 631 98.6% Other income 2,692 4,655 -42.2% 3,945 5,286 -25.4% Less: Expenses R&D investment (10,640) (10,917) -2.5% Other operating costs (1,976)
Slide 18: Full Year Cashflow
Full Year Cashflow 30 June 30 June For personal use only 2020 2019 Mvt $’000 $’000 Operating Activities Receipts from product agreements 1,093 576 89.8% Payments to suppliers and employees - 11,666 - 13,233 -11.8% Interest received 216 611 -64.6% Income taxes refunded/paid - 51 -100.0% Finance costs
Slide 19: CEO – Michael Kotsanis
For personal use only CEO – Michael Kotsanis
Slide 20: Future catalysts
Future catalysts For personal use only The success of Acrux’s strategy and management’s execution will be driven and measured by: ACRUX • Commercial launch and cash flow generation from new generic drugs STRATEGY • Licensing and profit share agreements with generic pharmaceutical companies • FDA app
Slide 21: Benefits of a Pooled Development Fund
BENEFITS OF A POOLED DEVELOPMENT FUND For personal use only 1 Companies with PDF status are taxed at 15% on their income and capital gains received from their investments 2 Australian resident shareholders are exempt from capital gains tax after selling their shares 3 Unfranked dividends received by
Slide 22: Thank you
For personal use only Thank you Michael Kotsanis CEO & Managing Director Acrux Limited P: + 61 3 8379 0100 E: michael.kotsanis@acrux.com.au Visit our website: http://www.acrux.com.au/ Follow us on LinkedIn:
Slide 23: Chairman – Ross Dobinson
For personal use only Chairman – Ross Dobinson
Slide 24: Formal Business
For personal use only Formal Business To receive and consider the Financial Report and the Report of the Directors and Auditor for the year ended 30 June 2020.
Slide 25: Resolution: Re-election of Mr Ross Dobinson as a Director
For personal use only Resolution 1 Re-election of Mr Ross Dobinson as a Director
Slide 26: Resolution: Adoption of Remuneration Report
For personal use only Resolution 2 Adoption of Remuneration Report
Slide 27: Resolution: Approval of 10% Placement Capacity - Shares
For personal use only Resolution 3 Approval of 10% Placement Capacity - Shares
Slide 28: Resolution: Approval of Omnibus Equity Plan
For personal use only Resolution 4 Approval of Omnibus Equity Plan – to refresh approval as required by the ASX Listing Rules
Slide 29: Resolution: Grant of rights to Mr Norman Gray
For personal use only Resolution 5 Grant of rights to Mr Norman Gray